Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Can Smart Cities Solve Overcrowding in China?

IoT exists to solve the problems in the world. Today’s episode focuses in on two areas where IoT could be incredibly beneficial: overcrowded cities and healthcare. Paul Doherty from The Digit Group joins the show to explain how smart city technology can help stem the tide of overcrowding in China. In our second feature…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

IoT exists to solve the problems in the world. Today’s episode focuses in on two areas where IoT could be incredibly beneficial: overcrowded cities and healthcare. Paul Doherty from The Digit Group joins the show to explain how smart city technology can help stem the tide of overcrowding in China. In our second feature on the show, Irma Rastegayeva speaks to Shelby Skrhak about IoT advancements in the field of healthcare.

How Mass Migration is Pushing Smart City Technology in China

Mass migration into urban centers is causing overcrowding in some of the largest cities in the world, specifically in China. How can smart city technology begin to help solve that problem? Paul Doherty, the Founder and CEO of The Digit Group, joined the podcast to explain the solutions and where they’re heading in the future.

“The idea is to provide these environments for great innovation…so that people will feel comfortable enough to start to settle down and raise their families,” says Doherty. The goal here is to add this technology to the less populated cities so people can build comfortable lives there, rather than moving to the already overcrowded city centers.

Recapping the Largest Healthcare and IoT Conference

More than 43,000 people attended the 2019 Healthcare Information and Management Systems Society conference, — HIMSS for short — that took place Feb. 11-15 in Orlando. Among them was Irma Rastegayeva. She is an industry-noted expert in Connected Health and IoT, and co-founder of eVIRa Health, a social media consultancy for healthtech startups.

Rastegayeva points out several applications of technology and Iot that really impressed her in this episode. One was ETHAN that stands for Emergency Telehealth and Navigation that’s been rolled out in the city of Houston.

“What I was particularly impressed was the clear results,” Rastegayeva tells Marketscale IoT. “Houston emergency center receives 9,000 calls daily, but it turns out only 30% of those are true emergencies. When they’re able to properly triage and offer guidance to patient, they save a lot of money and help improve the patient experience so they don’t have to go to an emergency room and spend 8 hours there.”

For the latest news, videos, and podcasts in the IoT Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @IOTMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512